Vericel Corporation to Release Q3 Financial Results Soon
Vericel Corporation, known for its cutting-edge therapies in sports medicine and severe burn care, is all set to share its financial results for the third quarter. The anticipated announcement will take place in the near future, allowing stakeholders and the investing community to gauge the company’s performance during this period.
Details of the Financial Results Announcement
The financial results announcement is scheduled for a Thursday morning, where management plans to hold a conference call. This call will begin at 8:30 a.m. ET, providing an opportunity for leadership to discuss the financial performance and address key highlights of the business. This event is designed to give investors and analysts insights into the company’s direction and performance metrics.
Participating in the Live Conference Call
For those who wish to tune into the live discussion, the conference call can be accessed via the Investor Relations section of the Vericel website. Investors are encouraged to join at least 15 minutes early to facilitate registration and ensure they have the necessary audio capabilities. During the call, Vericel aims to provide an overview of its financial results, along with discussions on market positioning and strategic initiatives.
Vericel's Innovative Product Portfolio
Vericel is proud to present a highly advanced portfolio of products that cater to the needs of various medical fields. Among their offerings is MACI, an innovative solution employed for repairing significant cartilage defects in the knee. This unique product harnesses autologous cultured chondrocytes on a specialized collagen membrane, demonstrating the company's commitment to blending biology with technology.
Expanding Access to Advanced Therapies
Epicel is another of Vericel's remarkable products, providing permanent skin replacement for patients affected by severe burns, making significant strides in recovery options for extensive burn injuries. Furthermore, through an exclusive licensing agreement for North American rights, Vericel also offers NexoBrid, an advanced biological product aimed at eschar removal, showcasing the company's dedication to restoring quality of life for patients post-injury.
Company Mission and Vision
Vericel's mission is centered on innovating healthcare solutions that heal and enhance lives. The team is continuously working on refining their therapies and exploring new avenues of treatment to stay at the forefront of medical advancements.
Contact Information for Investors
For interested parties wanting to discuss more about the company’s financial health or product details, Vericel welcomes engagement. They have designated Eric Burns for investor relations inquiries, who can be reached at ir@vcel.com or by calling +1 (734) 418-4411. Additionally, media inquiries can be directed to Julie Downs at media@vcel.com. This open line of communication underscores Vericel's commitment to transparency and partnership with stakeholders.
Frequently Asked Questions
What date will Vericel announce its third-quarter results?
Vericel will announce its financial results on a Thursday in the near future.
How can I access the financial results conference call?
The conference call will be accessible via the Investor Relations section of Vericel's website, and participants should log in 15 minutes prior to the start.
Who should I contact for investor relations questions?
For investor inquiries, reach out to Eric Burns at ir@vcel.com or call +1 (734) 418-4411.
What products does Vericel offer?
Vericel offers several advanced therapies, including MACI, Epicel, and has rights for NexoBrid in North America.
What is Vericel's mission?
Vericel's mission focuses on advancing the quality of life by developing innovative healthcare solutions for sports medicine and burn recovery.
